Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Is low-dose transdermal testosterone augmentation beneficial for women with antidepressant-resistant MDD?

Key clinical point: Low-dose transdermal testosterone augmentation for 8 weeks had no benefit over placebo in women with antidepressant-resistant major depressive disorder (MDD).

Major finding: The Montgomery-├ůsberg Depression Rating scores decreased from baseline to week 8 in testosterone group (from 26.8 to 15.3) and placebo groups (from 26.3 to 14.4), with no significant between-group difference (P = .91). No significant differences were observed between placebo and treatment groups in terms of fatigue and sexual function or side effects.

Study details: An 8-week, randomized, double-blind, placebo-controlled trial of adjunctive testosterone cream in 101 women (aged 21-70 years) with antidepressant-resistant MDD.

Disclosures: No study sponsor was identified. The authors reported individual grants from various sources. The authors reported ties with various pharmaceutical companies.


Dichtel LE et al. Am J Psychiatry. 2020 Jul 14. doi: 10.1176/appi.ajp.2020.19080844.